Kooij Louise Frederika
Insider CIK 2004379 · NAMS Chief Accounting Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-07-20 | 2026-07-22 | 25,000 | — | $0 | 10,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-07-20 | 2026-07-22 | 80,000 | — | $0 | 70,494 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-07-20 | 2026-07-22 | 25,000 | $11.90 | $297.5K | 49,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-07-20 | 2026-07-22 | 80,000 | $11.17 | $893.6K | 129,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-07-20 | 2026-07-22 | 70,200 | $29.96 | $2.10M | 59,153 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-07-20 | 2026-07-22 | 31,885 | $31.05 | $990.0K | 27,268 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-07-20 | 2026-07-22 | 2,915 | $31.71 | $92.4K | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-06-22 | 2026-06-24 | 25,000 | — | $0 | 43,134 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-06-22 | 2026-06-24 | 15,000 | — | $0 | 35,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-06-22 | 2026-06-24 | 39,700 | $30.20 | $1.20M | 24,653 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-06-22 | 2026-06-24 | 25,000 | $10.90 | $272.5K | 49,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-06-22 | 2026-06-24 | 15,000 | $11.90 | $178.5K | 64,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-06-22 | 2026-06-24 | 300 | $30.73 | $9.2K | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-05-26 | 2026-05-27 | 60,000 | — | $0 | 80,015 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-05-26 | 2026-05-27 | 5,000 | — | $0 | 68,134 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-05-26 | 2026-05-27 | 60,000 | $10.00 | $600.0K | 84,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-05-26 | 2026-05-27 | 65,000 | $35.69 | $2.32M | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-05-26 | 2026-05-27 | 5,000 | $10.90 | $54.5K | 89,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-01-28 | 2026-01-29 | 32,612 | — | $0 | 73,134 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-28 | 2026-01-29 | 32,612 | $31.80 | $1.04M | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-01-28 | 2026-01-29 | 32,612 | $10.90 | $355.5K | 56,965 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-01-27 | 2026-01-29 | 39,816 | — | $0 | 105,746 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-01-27 | 2026-01-29 | 39,816 | $10.90 | $434.0K | 64,169 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-27 | 2026-01-29 | 39,816 | $32.62 | $1.30M | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-01-26 | 2026-01-27 | 34,400 | — | $0 | 145,562 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-26 | 2026-01-27 | 309 | $33.45 | $10.3K | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-26 | 2026-01-27 | 34,091 | $32.77 | $1.12M | 24,662 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-01-26 | 2026-01-27 | 34,400 | $10.90 | $375.0K | 58,753 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-01-23 | 2026-01-27 | 38,172 | — | $0 | 179,962 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-23 | 2026-01-27 | 12,767 | $34.37 | $438.8K | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-23 | 2026-01-27 | 25,405 | $33.44 | $849.5K | 37,120 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-01-23 | 2026-01-27 | 38,172 | $10.90 | $416.1K | 62,525 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2026-01-07 | 2026-01-07 | 53,500 | — | $0 | 53,500 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2026-01-07 | 2026-01-07 | 12,000 | — | $0 | 24,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-05 | 2026-01-07 | 2,647 | $33.25 | $88.0K | 12,353 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-12-26 | 2025-12-29 | 38,872 | — | $0 | 140,015 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-12-26 | 2025-12-29 | 5,000 | — | $0 | 218,134 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-12-26 | 2025-12-29 | 43,872 | $35.30 | $1.55M | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-12-26 | 2025-12-29 | 5,000 | $10.90 | $54.5K | 58,872 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-12-26 | 2025-12-29 | 38,872 | $10.00 | $388.7K | 53,872 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-12-24 | 2025-12-29 | 26,011 | — | $0 | 178,887 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-12-24 | 2025-12-29 | 26,011 | $10.00 | $260.1K | 41,011 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-12-24 | 2025-12-29 | 26,011 | $35.68 | $928.1K | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-12-23 | 2025-12-29 | 75,117 | — | $0 | 204,898 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-12-23 | 2025-12-29 | 75,117 | $10.00 | $751.2K | 90,117 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-12-23 | 2025-12-29 | 75,117 | $36.21 | $2.72M | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-09-09 | 2025-09-10 | 150,000 | — | $0 | 280,015 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-09-09 | 2025-09-10 | 53,104 | $25.31 | $1.34M | 111,896 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-09-09 | 2025-09-10 | 150,000 | $10.00 | $1.50M | 165,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-09-09 | 2025-09-10 | 96,896 | $26.11 | $2.53M | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-09-03 | 2025-09-05 | 18,073 | $25.09 | $453.5K | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-09-02 | 2025-09-04 | 18,073 | — | $0 | 0 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-09-02 | 2025-09-04 | 18,073 | — | $0 | 33,073 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-08-25 | 2025-08-27 | 8,269 | $24.86 | $205.6K | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-03-26 | 2025-03-28 | 8,269 | — | $0 | 0 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-03-26 | 2025-03-28 | 8,269 | — | $0 | 8,269 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-03-26 | 2025-03-28 | 8,269 | — | $0 | 23,269 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-03-04 | 2025-03-05 | 150,000 | — | $0 | 18,073 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-03-04 | 2025-03-05 | 150,000 | $20.37 | $3.06M | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-03-04 | 2025-03-05 | 150,000 | — | $0 | 165,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2025-01-07 | 2025-01-07 | 15,000 | — | $0 | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-01-02 | 2025-01-06 | 80,000 | — | $0 | 80,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2024-10-01 | 2024-10-01 | 45,000 | $15.72 | $707.4K | 0 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2024-09-27 | 2024-10-01 | 45,000 | — | $0 | 168,073 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2024-09-27 | 2024-10-01 | 45,000 | — | $0 | 45,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2024-01-01 | 2024-01-03 | 150,494 | — | $0 | 150,494 | SEC↗ |